NASDAQ:RDUS - Radius Health Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.60
  • Forecasted Upside: -14.68 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$10.08
▼ -0.02 (-0.20%)

This chart shows the closing price for RDUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Radius Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDUS

Analyst Price Target is $8.60
▼ -14.68% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Radius Health in the last 3 months. The average price target is $8.60, with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a -14.68% upside from the last price of $10.08.

This chart shows the closing price for RDUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Radius Health. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/24/2022SVB LeerinkBoost Price TargetMarket Perform$7.00 ➝ $10.00Low
6/8/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$8.00Low
5/24/2022The Goldman Sachs GroupLower Price TargetNeutral$9.00 ➝ $8.00Low
5/23/2022SVB LeerinkInitiated CoverageMarket Perform$7.00Medium
12/10/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$18.00 ➝ $7.00High
12/9/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$33.00 ➝ $12.00High
12/9/2021HC WainwrightLower Price TargetNeutral ➝ Neutral$23.00 ➝ $10.00High
12/9/2021SVB LeerinkReiterated RatingHold$30.00 ➝ $20.00High
12/3/2021Bank of AmericaInitiated CoverageUnderperform$16.00Low
11/9/2021SVB LeerinkBoost Price TargetMarket Perform$29.00 ➝ $30.00High
11/9/2021HC WainwrightLower Price TargetNeutral$26.00 ➝ $23.00High
10/21/2021SVB LeerinkBoost Price TargetMarket Perform$26.00 ➝ $29.00Medium
10/21/2021HC WainwrightBoost Price TargetPositive ➝ Neutral$19.00 ➝ $26.00Medium
10/20/2021The Goldman Sachs GroupBoost Price TargetPositive ➝ Buy$31.00 ➝ $33.00High
10/19/2021HC WainwrightReiterated RatingHold$19.00Medium
10/13/2021Morgan StanleyLower Price TargetEqual Weight$19.00 ➝ $18.00Medium
8/6/2021SVB LeerinkBoost Price TargetMarket Perform$24.00 ➝ $26.00High
8/6/2021HC WainwrightLower Price TargetNeutral$25.00 ➝ $19.00High
5/18/2021Morgan StanleyBoost Price TargetEqual Weight$19.00 ➝ $20.00Low
5/10/2021SVB LeerinkBoost Price TargetMarket Perform$23.00 ➝ $24.00High
5/10/2021HC WainwrightReiterated RatingHold$25.00High
3/22/2021The Goldman Sachs GroupReiterated RatingBuy$33.00N/A
3/1/2021SVB LeerinkBoost Price TargetMarket Perform$20.00 ➝ $23.00Low
2/24/2021HC WainwrightBoost Price TargetNeutral$22.00 ➝ $25.00High
1/7/2021SVB LeerinkBoost Price TargetMarket Perform$17.00 ➝ $20.00N/A
1/7/2021Smith Barney CitigroupBoost Price Target$25.00 ➝ $30.00N/A
1/7/2021HC WainwrightReiterated RatingHoldN/A
10/22/2020HC WainwrightLower Price TargetNeutral$28.00 ➝ $22.00High
10/4/2020HC WainwrightReiterated RatingHold$28.00High
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
8/28/2020SVB LeerinkReiterated RatingMarket PerformHigh
8/25/2020Morgan StanleyLower Price TargetEqual Weight$20.00 ➝ $19.00Medium
8/11/2020CitigroupLower Price TargetBuy$39.00 ➝ $25.00Low
8/11/2020Jefferies Financial GroupLower Price TargetNeutral ➝ Hold$17.00 ➝ $14.00Low
7/28/2020HC WainwrightReiterated RatingHold$28.00Low
7/24/2020SVB LeerinkBoost Price TargetMarket Perform$17.00 ➝ $18.00High
7/8/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$34.00 ➝ $17.00High
5/13/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$20.00High
5/12/2020JPMorgan Chase & Co.Lower Price TargetOverweight$32.00 ➝ $27.00High
5/8/2020HC WainwrightReiterated RatingHold$28.00High
4/23/2020Stifel NicolausInitiated CoverageHold$20.00High
4/15/2020Morgan StanleyLower Price TargetOverweight$33.00 ➝ $32.00High
3/6/2020Morgan StanleyLower Price TargetOverweight$36.00 ➝ $33.00High
2/28/2020HC WainwrightBoost Price TargetNeutral$27.00 ➝ $28.00High
12/20/2019HC WainwrightReiterated RatingHoldHigh
11/7/2019HC WainwrightReiterated RatingHold$27.00High
11/6/2019SVB LeerinkLower Price TargetOutperform$49.00 ➝ $35.00High
11/1/2019Royal Bank of CanadaSet Price TargetHold$27.00High
9/5/2019Morgan StanleyInitiated CoverageBuy$43.00Low
8/29/2019CitigroupUpgradeNeutral ➝ Buy$24.00 ➝ $40.00High
8/8/2019CowenReiterated RatingHoldHigh
5/30/2019CitigroupReiterated RatingNeutral$24.00Low
5/29/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$26.00 ➝ $38.00Medium
5/9/2019HC WainwrightReiterated RatingHoldLow
5/8/2019CowenReiterated RatingHoldLow
2/14/2019HC WainwrightInitiated CoverageNeutral$22.00High
11/6/2018CowenReiterated RatingHoldMedium
11/2/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$59.00 ➝ $52.00Low
10/18/2018CowenReiterated RatingHoldMedium
8/7/2018Jefferies Financial GroupReiterated RatingHold$25.00Medium
7/25/2018Bank of AmericaLower Price TargetBuy ➝ Buy$51.00 ➝ $47.00Medium
7/23/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ $28.40$60.00 ➝ $59.00High
6/11/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$56.00 ➝ $60.00High
6/11/2018Cantor FitzgeraldSet Price TargetBuy$58.00High
5/11/2018Cantor FitzgeraldReiterated RatingBuy$58.00High
3/29/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$53.00Medium
3/23/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$61.00 ➝ $59.00Low
3/22/2018Cantor FitzgeraldSet Price TargetBuy$58.00High
3/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $61.00High
2/12/2018JPMorgan Chase & Co.Lower Price TargetOverweight$70.00 ➝ $60.00Medium
1/29/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$57.00Medium
1/22/2018CitigroupReiterated RatingHold$43.00Medium
1/18/2018Cantor FitzgeraldReiterated RatingBuy$58.00High
12/15/2017Cantor FitzgeraldSet Price TargetBuy$58.00High
12/7/2017Cantor FitzgeraldSet Price TargetBuy$58.00High
12/6/2017CitigroupInitiated CoverageNeutral ➝ Neutral$30.00Medium
11/3/2017Cantor FitzgeraldReiterated RatingBuy$58.00N/A
11/3/2017Jefferies Financial GroupLower Price TargetHold$38.00 ➝ $31.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$45.00N/A
9/29/2017Maxim GroupReiterated RatingPositiveMedium
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/14/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/13/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/15/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
5/14/2022
  • 8 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
6/13/2022
  • 9 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/13/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Radius Health logo
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $10.08
Low: $10.06
High: $10.18

50 Day Range

MA: $9.56
Low: $6.58
High: $10.84

52 Week Range

Now: $10.08
Low: $4.97
High: $23.00

Volume

6,483,912 shs

Average Volume

1,172,196 shs

Market Capitalization

$479.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Radius Health?

The following Wall Street research analysts have issued reports on Radius Health in the last year: Bank of America Co., HC Wainwright, Morgan Stanley, StockNews.com, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for RDUS.

What is the current price target for Radius Health?

5 Wall Street analysts have set twelve-month price targets for Radius Health in the last year. Their average twelve-month price target is $8.60, suggesting a possible downside of 14.9%. SVB Leerink LLC has the highest price target set, predicting RDUS will reach $10.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $7.00 for Radius Health in the next year.
View the latest price targets for RDUS.

What is the current consensus analyst rating for Radius Health?

Radius Health currently has 1 sell rating and 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RDUS, but not buy more shares or sell existing shares.
View the latest ratings for RDUS.

What other companies compete with Radius Health?

How do I contact Radius Health's investor relations team?

Radius Health's physical mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company's listed phone number is (617) 551-4000 and its investor relations email address is [email protected] The official website for Radius Health is www.radiuspharm.com. Learn More about contacing Radius Health investor relations.